Polyethylene glycol in the design of tumor-targetting radiolabelled macromolecules - Lessons from liposomes and monoclonal antibodies

Quarterly Journal of Nuclear Medicine

Volumn 46, Issue 3, 2002, Pages 171-180

  Harrington, Kevin J ^a   Mubashar, M ^a   Peters, A M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Liposomes; Monoclonal antibodies; Neoplasms; Radionuclide imaging; Radiopharmaceuticals

Indexed keywords

ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; ASPARAGINASE; BACTERIAL PROTEIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CETUXIMAB; CETUXIMAB IN 111 PLUS MACROGOL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A5B7; MONOCLONAL ANTIBODY IN 111; MONOSIALOGANGLIOSIDE; PENTETATE INDIUM IN 111 CETUXIMAB; PENTETATE INDIUM IN 111 PLUS MACROGOL LIPOSOME; PENTETIC ACID; PHOSPHATIDYLINOSITOL; RADIOPHARMACEUTICAL AGENT; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; UNCLASSIFIED DRUG;

CANCER; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; EXPERIMENTAL MODEL; HUMAN; ISOTOPE LABELING; MACROMOLECULE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MEDICINE; RADIOIMMUNOTHERAPY; REVIEW; TUMOR; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MACROMOLECULAR SUBSTANCES; NEOPLASMS; POLYETHYLENE GLYCOLS; RADIOIMMUNOTHERAPY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036749888     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50(3 Suppl):814s-9.
2. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
3. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
4. Harrington KJ, Lewanski CR, Stewart JS. Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development. Clin Oncol (R Coll Radiol) 2000;12;2-15.
5. Harrington KJ. Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin Investig Drugs 2001;10:1045-61.
6. Dillman RO. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest 2001;19:833-41.
7. Bischof Delaloye A. Radioimmunoimaging and radioimmunotherapy: will these be routine procedures? Semin Nucl Med 2000;30:186-94.
8. Van Kroonenburgh MJ, Pauwels EK. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun. 1988;9:919-30.
9. Lasic DD, Papahadjopoulos D. Liposomes revisited. Science 1995;267:1275-6.
10. Ranson M, Howell A, Cheeseman S, Margison J. Liposomal drug delivery. Cancer Treat Rev 1996;22:365-79.
11. Bangham AD, Standish HM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.
12. Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res 1968;9:310-8.
13. Gregoriades G, Swain CP, Wills EJ, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1974;1:1313-6.
14. Gregoriadis G. The carrier potential of liposomes in biology and medicine (Part 1). N Engl J Med 1976;295:704-10.
15. Gregoriadis G. The carrier potential of liposomes in biology and medicine (Part 2). N Engl J Med 1976;295:765-70.
16. Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology 1997;11 (Suppl 11): 11-20.
17. Durocher JR, Payne RC, Conrad ME. Role of sialic acid in erythrocyte survival. Blood 1975;45:11-20.
18. Allen TM, Chonn A. Large unilamellar liposomes with low uptake by the reticuloendothelial system. FEBS Lett 1987;223:42-6.
19. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumours. Proc Natl Acad Sci USA 1988;85:6949-53.
20. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation times of liposomes. FEBS Lett 1990;268:235-7.
21. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Lee KD et al. Sterically stabilised liposomes: improvements in pharmacokinetics and anti-tumour therapeutic efficacy. Proc Natl Acad Sci USA 1991;88:11460-4.
22. Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C et al. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1992;1105:193-200.
23. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991;1070:187-92.
24. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North America 1994;8:431-50.
25. Lasic DD. Doxorubicin in sterically stabilised liposomes. Nature 1996;380:561-2.
26. Harrington KJ, Lewanski CR, Stewart JS. Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clin Oncol (R Coll Radiol) 2000;12:16-24.
27. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R et al. Phase I trial of 40-kd branched pegylated interferon α-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001;19:1312-9.
28. Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY et al. Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol 2002;20:24-36.
29. Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000;95:2530-5.
30. Holle LM. Pegaspargase: an alternative? Ann Pharmacother 1997;31:616-24.
31. Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:1709-15.
32. Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;47:83-8.
33. Pedley RB, Boden JA, Boden R, Begent RH, Turner A, Haines AM et al. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994;70:1126-30.
34. 111In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med. 2001;42:1530-7.
35. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
36. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
37. Delgado C, Pedley RB, Herraez A, Boden R, Boden JA, Keep PA et al. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab′ fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996;73:175-82.
38. Ledermann JA, Begent RH, Bagshawe KD, Riggs SJ, Searle F, Glaser MG et al. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer 1988;58:654-7.
39. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355:735-740.
40. Deckert PM, Jungbluth A, Montalto N, Clark MA, Finn RD, Williams C Jr et al. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targetting colon cancer xenografts. Int J Cancer 2000;87:382-90.
41. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targetting strategies. Br J Cancer 2000;83:232-8.
42. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG et al. Effective targetting of solid tumors in patients with locally advanced cancers by radiolabelled pegylated liposomes. Clin Cancer Res 2001;7:243-54.
43. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol. 1999;17:3512-21.
44. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A et al. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas - rationale for combination with radiotherapy. Acta Oncol 2000;39:207-11.
45. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 2000;83:1281-6.
46. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Abra RM, Uster PS, Peters AM et al. Influence of tumour size on uptake of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer 2000;83:684-8.
47. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Peters AM et al. The effect of irradiation on the biodistribution of radiolabelled pegylated liposomes. Int J Radiat Oncol Biol Phys 2001;50:809-20.
48. Harrington KJ, Rowlinson-Busza G, Uster PS, Vile RG, Peters AM, Stewart JS. Single-fraction irradiation has no effect on uptake of radiolabelled pegylated liposomes in a tumor xenograft model. Int J Radiat Oncol Biol Phys 2001;49:1141-8.
49. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Stewart JS. Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery. Clin Cancer Res 2000;6:2528-37
50. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 2000;41:622-30.
51. Boerman OC, Laverman P, Oyen WJ, Corstens FH, Storm G. Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res. 2000;39:461-75.